Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $19.00

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $19.00.

A number of equities analysts recently commented on FULC shares. Leerink Partners reiterated an “outperform” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Royal Bank Of Canada upped their target price on Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a report on Monday, December 8th. Stifel Nicolaus set a $25.00 price target on Fulcrum Therapeutics in a report on Monday, December 8th. Truist Financial set a $17.00 price target on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Fulcrum Therapeutics in a report on Monday, January 12th. They issued an “overweight” rating and a $20.00 price objective for the company.

Fulcrum Therapeutics Trading Down 2.1%

Shares of NASDAQ FULC opened at $7.63 on Tuesday. The stock has a market cap of $508.16 million, a PE ratio of -6.47 and a beta of 3.23. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $15.74. The company has a 50-day moving average of $9.90 and a 200 day moving average of $9.57.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Tuesday, February 24th. The company reported ($0.31) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.31). On average, sell-side analysts forecast that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Robert J. Gould sold 15,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the sale, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This represents a 3.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 7.00% of the stock is owned by insiders.

Institutional Trading of Fulcrum Therapeutics

Institutional investors have recently made changes to their positions in the company. Invesco Ltd. lifted its holdings in Fulcrum Therapeutics by 236.8% in the fourth quarter. Invesco Ltd. now owns 417,189 shares of the company’s stock valued at $4,718,000 after acquiring an additional 293,317 shares during the last quarter. XTX Topco Ltd acquired a new stake in Fulcrum Therapeutics during the fourth quarter worth $586,000. Ikarian Capital LLC raised its position in Fulcrum Therapeutics by 6.7% in the fourth quarter. Ikarian Capital LLC now owns 1,375,472 shares of the company’s stock valued at $15,557,000 after purchasing an additional 86,247 shares during the period. Vestal Point Capital LP purchased a new stake in Fulcrum Therapeutics in the fourth quarter valued at $10,744,000. Finally, Virtus Investment Advisers LLC acquired a new position in shares of Fulcrum Therapeutics in the 4th quarter valued at $231,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.